Activated Matrix Metalloproteinase-2-A Potential Marker of Prognosis for Epithelial Ovarian Cancer

By Wu X.   Li H.   Kang L.   Li L.   Wang W.   Shan B.  

Gynecologic Oncology, Vol. 84, Iss. 1, 2002-01 ,pp. : 126-134

Elsevier

Access to resources Recommend Favorite

EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma

By Davidson Ben   Goldberg Iris   Berner Aasmund   Kristensen Gunnar   Reich Reuven  

Clinical and Experimental Metastasis, Vol. 20, Iss. 2, 2003-03 ,pp. : 161-169

Springer Publishing Company

Access to resources Recommend Favorite

Matrix metalloproteinases (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases (MAPK): Co-expression in metastatic serous ovarian carcinoma

By Davidson Ben   Givant-Horwitz Vered   Lazarovici Philip   Risberg Björn   Nesland Jahn   Trope Claes   Schaefer Erik   Reich Reuven  

Clinical and Experimental Metastasis, Vol. 20, Iss. 7, 2003-11 ,pp. : 621-631

Springer Publishing Company

Access to resources Recommend Favorite

Extracellular matrix metalloproteinase inducer and matrix metalloproteinase-2 overexpression is associated with loss of hormone receptor expression and poor prognosis in endometrial cancer

By          

Oncology Letters, Vol. 10, Iss. 1, 2015-01 ,pp. : 342-348

Spandidos Publications

Access to resources Recommend Favorite

AG1478 inhibits the migration and invasion of cisplatinresistant human lung adenocarcinoma cells via the cell cycle regulation by matrix metalloproteinase9

By      

Oncology Letters, Vol. 8, Iss. 2, 2014-01 ,pp. : 921-927

Spandidos Publications

Access to resources Recommend Favorite